Deal facts
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Announced
- 10 November 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash, shares, deferred
Sources
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities Purchase Agreement is dated 9 November 2026. MaxCyte announced the deal in a press release on 10 November 2026, and the 8-K covering it was accepted by the SEC the same day. The sellers are Ohio TopCo LP and Arcline Capital Partners A LP. MaxCyte will acquire all of the outstanding equity interests of Akron indirectly. Akron is a Boca Raton, Florida supplier of GMP-grade reagents and ancillary materials used in cell therapy manufacturing.
MaxCyte puts the total consideration at $151.8 million. It has three parts. The first is $105.0 million in cash payable at closing, subject to customary adjustments. The second is 20,639,733 newly issued MaxCyte shares, which MaxCyte values at approximately $26.8 million based on the 9 November 2026 closing price. The third is $20.0 million in guaranteed deferred cash payments, made up of $10.0 million on the first business day of 2028 and $10.0 million on the first business day of 2029. The filing says the deferred payments may become immediately due on certain events, including a change of control of MaxCyte, a payment default, insolvency or the acceleration of certain other indebtedness.
MaxCyte says Akron is expected to generate approximately $28 million in revenue and $7-8 million in EBITDA in 2026, with positive cash flow. EBITDA is a non-GAAP measure. MaxCyte also reported a new credit facility with MidCap Financial of up to $75.0 million, consisting of a $55.0 million term loan and a $20.0 million revolver. It expects to draw $20.0 million of the term loan and $2.0 million of the revolver at closing. MaxCyte says it will fund the acquisition with cash on hand and newly issued common stock.
Closing requires the expiration or termination of the Hart-Scott-Rodino waiting period and approval of the new shares for listing on Nasdaq. It does not require a financing condition or a vote of MaxCyte stockholders. The parties expect to close before the end of 2026, and the agreement may be terminated if closing has not occurred within 120 days of the agreement date. The sellers' shares will be subject to a six-month lock-up after closing, and a registration rights agreement will cover their resale. MaxCyte has also obtained a conditional binder for a buyer-side representations and warranties insurance policy. That policy is its sole recourse for breaches of the sellers' representations, except for fraud. Stifel is MaxCyte's financial advisor and Sidley Austin LLP its legal counsel. Jefferies LLC is advising Arcline.
The archive tags include deferred consideration. Compare completion cash, deferred payments and earn-outs before treating a headline amount as proceeds. Check the underlying announcement for the actual conditions; tags are not a complete payment schedule.
Deal timeline
1 update- Firm intention
MaxCyte, Inc. firm intention to acquire Akron BioProducts LLC
Item 1.01. Entry into a Material Definitive Agreement. On November 9, 2026, MaxCyte, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with Ohio TopCo LP and Arcline Capital Partners A LP (together, the “ Sellers ”), affiliates of Arcline Investment Management, and the other parties thereto, pursuant to which the Company will acquire, indirectly, all
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Drugs Made In America Acquisition II Corp. to acquire Alpha AI Biotech Group
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that…
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Deal type
- strategic acquisition
Aimei Health Technology Co., Ltd to acquire Hera Health Solutions Inc.
Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business co…
- Buyer
- Aimei Health Technology Co., Ltd
- Target
- Hera Health Solutions Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Wolfram Resources Plc to acquire Ellipses Pharma Limited
Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a poten…
- Buyer
- Wolfram Resources Plc
- Target
- Ellipses Pharma Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
New Horizon Pharma B.V. to acquire Phatebo GmbH
ZeroStack Corp. disclosed in a Form 8-K, accepted by the SEC on 9 November 2026, that on 3 November 2026 it signed a Share Purchase and Transfer Agreement with New Horiz…
- Buyer
- New Horizon Pharma B.V.
- Target
- Phatebo GmbH
- Deal value
- EUR 2,150,000
- Deal type
- strategic acquisition
Buyer history
MaxCyte, Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive